San Diego and Cologne, Germany–ACEA Biosciences (ACEA), a pioneer and leader in label-free real-time cell analysis instrumentation, and Ncardia, a leading expert in human cardiovascular stem cell technology, disease modelling and cell-based assay products and services, announced today that they have established a global partnership to provide comprehensive solutions for cardiac drug discovery and cardiac safety assessment. This multifaceted partnership will include the joint development of applications, co-marketing, and commercial activities. Central to this partnership will be the coupling of ACEA’s innovative xCELLigence® Real-Time Cell Analysis (RTCA) Cardio and CardioECR instruments with Ncardia’s fully functional Pluricyte® and Cor.4U® human iPSC-derived cardiomyocytes, providing a complete assay system for pure and applied cardiomyocyte research.
Ncardia Signs License Agreement with First Pharmaceutical Partner for Disease Modeling Patent Portfolio
October 12, 2017, COLOGNE, Germany–Roche and Ncardia have reached a broad licensing agreement whereby Roche and its affiliate companies gain access to key disease modeling patents from Ncardia.
Ncardia was recently formed through the merger of Axiogenesis and Pluriomics. The two companies have pioneered the development of stem cell derived cells for drug discovery and safety and in particular have advanced disease and tissue modeling applications.
The Ncardia patent portfolio consists of several granted patents in Europe, the USA and Japan. The drug screening and disease modeling technology not only involves patient iPSC cells, induction of the disease phenotype can also be achieved through genetic manipulation, mRNA or siRNA transfection or through chemical or physical induction. [Read more…]
Axiogenesis AG and Pluriomics B.V. are combining forces to form Ncardia, the new global authority in cardiac and neural applications of human induced pluripotent stem cells (iPSCs).
Founded in 2001, Axiogenesis AG has Cologne (DE) and Philadelphia (USA) facilities, while Pluriomics B.V. has facilities in Gosselies (BE) and Leiden (NL). By entering into this merger, these European leaders will become the global leader in hiPSC drug discovery and development field, making Ncardia the partner of choice for scientists conducting cardiovascular and neural safety and efficacy projects.
By combining their global client base, the merger of Axiogenesis and Pluriomics will position Ncardia as a leader in standardized, validated iPSC assays for safety, phenotypic screening and disease modelling. For scientists conducting cardiovascular and neural safety and efficacy projects, Ncardia will provide tools to facilitate accelerated development of drugs, while replacing animal studies and putting a “human” aspect back into drug discovery.
According to Felix Haniel, VP Business Development & Sales of Ncardia: “Our vision is to develop products and services that are a complete solution. We will produce human iPSC derived cardiovascular and neuronal cell types and realize validated electrophysiology, biochemistry and contraction based assays. By combining over two decades of experience, Ncardia will offer iPSC assays for safety pharmacology, toxicology testing, drug efficacy screening, phenotypic screening, and disease modelling.”
Founded in 2001 as a spin-off of the University of Cologne, Axiogenesis initially focused on generating mouse embryonic stem cell derived cells and assays. After Yamanaka’s groundbreaking iPSC technology became available, Axiogenesis was the first European company to license and adopt Yamanaka’s iPSC technology in 2010. Now Axiogenesis specializes in human induced pluripotent stem cell products, including in vitro models of healthy and diseased cell types and tissues. In 2014, Axiogenesis founded its American subsidiary in Philadelphia, PA. [Read more…]
Builds foundation to become the trusted leader in hiPSC based drug discovery solutions.
Gosselies (BE), Cologne (DE), Leiden (NL), Philadelphia (USA), September 18th 2017 – Ncardia (www.ncardia.com) has been established following the merger of Pluriomics and Axiogenesis. The privately held company with operations in Europe and the US, produces and commercializes high-quality, fully functional hiPSC derived cardiovascular and neuronal cell types and develops and realizes electrophysiology, biochemistry and contraction based assays for predictive safety pharmacology, toxicology testing and drug efficacy screenings. [Read more…]